Delivery Order SPE2DB24D2205-SPE2DB25FEHWZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,229.88 to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 mg/4 ml syringes on June 17, 2025, with an ultimate completion date of June 18, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. MONOVISC is a hyaluronic acid-based viscosupplement used for osteoarthritis pain management,...
- The Defense Logistics Agency awarded a $1,362.35 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Monovisc is a hyaluronic acid-based viscosupplement used for knee osteoarthritis treatment, indicating this...
- The Defense Logistics Agency awarded a delivery order valued at $2,962.22 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on September 5, 2025, with completion targeted for September 8, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used to treat osteoarthritis pain, representing one of the specialized...
- The Defense Logistics Agency awarded a $3,586.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on September 24, 2025, with an ultimate completion date of September 25, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $7,821.66 to AmerisourceBergen Drug Corp for MONOVISC 88 mg/4 mL syringes (4 mL quantity) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. MONOVISC is a hyaluronic acid injection used for the treatment of osteoarthritis knee...
- The Defense Logistics Agency awarded a delivery order valued at $14,829.77 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used in orthopedic and rheumatological...
- The Defense Logistics Agency awarded a delivery order valued at $3,711.30 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order for pharmaceutical supplies to be performed at the awardee's facility in Conshohocken, Pennsylvania. Monovisc is a hyaluronic acid injection used for joint pain management, reflecting the...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $6,811.06 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 8, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, is scheduled for completion by August 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used primarily for knee...
- The Defense Logistics Agency awarded a delivery order valued at $1,221.75 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes (4 ml quantity) on June 18, 2025, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used to treat osteoarthritis pain,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,551.43 on August 13, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This firm fixed-price delivery order, which carries an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used primarily for osteoarthritis joint pain...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHWZDelivery Order
The Defense Logistics Agency awarded a $29,144.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes (4 mL quantity) with an ultimate completion date of September 24, 2025. This non-competitive delivery order was awarded on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Monovisc is a hyaluronic acid-based viscosupplement used primarily for the treatment of osteoarthritis, particularly in the knee joint, and represents part of the company's broader pharmaceutical and medical supply portfolio supporting federal healthcare needs. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen has demonstrated consistent capability in fulfilling federal medical procurement requirements through open competition. The company supplies an extensive range of pharmaceutical products and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide, with this particular delivery order reflecting the ongoing pharmaceutical supply needs within the defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.1k | 9/23/25 |